The bridge decides what the certificate must show
A six-residue ring closed by a disulfide bond between two cysteines defines this molecule's conformation. Break that bond and you have the reduced linear form; let thiol exchange occur and you have a scrambled species. Either outcome can still present a mass in the right region while being a different thing from what the protocol names.
So a main-peak percentage is not an adequate release statement here. The related substances worth resolving explicitly are the reduced linear form and disulfide-scrambled species, and a certificate that reports neither is describing less than the method could. How to read a peptide COA covers how to work through the analytical block; the compound-specific point is simply to look for those two entries by name.
The handling rule follows directly. Keep reducing agents and thiol-containing buffer components away from the material unless the design specifically requires them, and treat buffer composition as part of the experimental design rather than as neutral background.
A licensed medicine with the same name is not this material
Oxytocin is a licensed medicine in obstetric practice in the UAE and internationally. That product is manufactured, released and distributed as a pharmaceutical. VaultLabs supplies a research reference material that is none of those things and is not for human or veterinary use.
Record it that way. The name collision is more complete here than for most of the catalogue — same active name, same spelling, entirely different supply chain — so the classification on a requisition and in an inventory system is doing real work. An institutional reviewer who sees only the compound name will reasonably assume the pharmaceutical unless the record says otherwise.
